From the *Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China; †Stanford University, Santa Clara Valley Medical Center, San Jose, CA; and ‡Department of Oncology, West China Hospital, Sichuan University, Chengdu, China.
Clin Nucl Med. 2015 Oct;40(10):767-73. doi: 10.1097/RLU.0000000000000892.
The prognostic value of FDG PET/CT in extranodal natural killer/T-cell lymphoma (ENKTL) is still controversial. Furthermore, the utility of the Deauville 5-point scale (DS) in ENKTL is uncertain. Therefore, we designed a prospective study to examine the prognostic value of 3 methods of PET/CT analysis (International Harmonization Project [IHP] criteria, DS, and SUV-based assessment).
Sixty patients with newly diagnosed untreated ENKTL were enrolled. PET/CT evaluation was performed before initial treatment (pretreatment) and midtreatment (interim). Interim PET/CT response was determined based on IHP criteria, DS, and change in FDG uptake (ΔSUVmax). International Harmonization Project criteria, DS, and ΔSUVmax were then examined for the ability to predict progression-free survival (PFS) and overall survival (OS).
Over a median follow-up of 23.5 months, interim PET/CT based on DS and ΔSUVmax were significant predictors of PFS and OS. After multivariate analysis, DS was an independent predictor of PFS (P < 0.001) and OS (P < 0.001). ΔSUVmax was an independent predictor of OS (P = 0.013) but not PFS (P = 0.054) and with a lower accuracy and positive predictive value than DS.
Interim PET/CT analysis with DS predicts unfavorable treatment outcomes of ENKTL patients, whereas interim PET/CT analysis based on IHP criteria and SUV-based assessment have limited prognostic value.
FDG PET/CT 对结外自然杀伤/T 细胞淋巴瘤(ENKTL)的预后价值仍存在争议。此外,Deauville5 分评分(DS)在 ENKTL 中的应用尚不确定。因此,我们设计了一项前瞻性研究,以检查 3 种 PET/CT 分析方法(国际协调项目[IHP]标准、DS 和 SUV 评估)的预后价值。
共纳入 60 例初治未经治疗的 ENKTL 患者。在初始治疗(预处理)前和中期(中期)进行 PET/CT 评估。根据 IHP 标准、DS 和 FDG 摄取变化(ΔSUVmax)评估中期 PET/CT 反应。然后检查 IHP 标准、DS 和 ΔSUVmax 对无进展生存(PFS)和总生存(OS)的预测能力。
在中位数为 23.5 个月的随访中,DS 和 ΔSUVmax 的中期 PET/CT 是 PFS 和 OS 的显著预测因素。多变量分析后,DS 是 PFS(P<0.001)和 OS(P<0.001)的独立预测因素。ΔSUVmax 是 OS 的独立预测因素(P=0.013),但不是 PFS(P=0.054),并且其准确性和阳性预测值均低于 DS。
DS 进行的中期 PET/CT 分析可预测 ENKTL 患者的不良治疗结局,而基于 IHP 标准和 SUV 评估的中期 PET/CT 分析的预后价值有限。